Bijzondere interventies aan het hart - Gezondheidsraad

21 Zijlstra F, Patel A, Jones M, Grines CL, Ellis S, Garcia E e.a. Clinical characteristics and outcome of
patients with early (4 h) presentation treated by primary coronary
angioplasty or thrombolytic therapy for acute myocardial infarction. Eur Heart J 2002;23:550-7.
22 Liem AL, van 't Hof AW, Hoorntje JC, de Boer MJ, Suryapranata H, Zijlstra F. Influence of treatment
delay on infarct size and clinical outcome in patients with acute myocardial infarction treated with
primary angioplasty. J Am Coll Cardiol 1998;32:629-33.
23 Liem AL, van 't Hof AW, Hoorntje JC, de Boer MJ, Suryapranata H, Zijlstra F. Influence of treatment
delay on infarct size and clinical outcome in patients with acute myocardial infarction treated with
primary angioplasty. J Am Coll Cardiol 1998;32:629-33.
24 Pocock SJ.Clinical trials. A practical approach. New-York John Wiley & Sons 1983
25 de Feyter PJ, McFadden E. Risk score for percutaneous coronary intervention: forewarned is forearmed.
J Am Coll Cardiol 2003;42:1729-30.
26 Singh M, Rihal CS, Selzer F, Kip KE, Detre K, Holmes DR. Validation of Mayo Clinic risk adjustment
model for in-hospital complications after percutaneous coronary interventions, using the National
Heart, Lung, and Blood Institute dynamic registry. J Am Coll Cardiol 2003;42:1722-8.
27 Ernst N, van 't Hof, van de Wetering H, Hollak F, de Pooter F, Suryapranata, Hoorntje JCA, Dambrink
JHE, Gosselink M, Zijlstra F, de Boer MJ of the On-TIME Study Group. Thesis Groningen mei
2005.
Analyse inzake veiligheid van PTCA in ziekenhuizen zonder hartchirurgie 297